血清干扰素调节因子1在类风湿关节炎中的临床意义

doi:10.11958/20251530

天津医药 ›› 2026, Vol. 54 ›› Issue (1): 84-87.doi: 10.11958/20251530

血清干扰素调节因子1在类风湿关节炎中的临床意义

李荣琪¹^,²(), 李宇轩³, 张燕¹^,², 李昕²^,⁴^,^△(), 魏蔚²^,⁴

1 天津医科大学总医院空港医院风湿免疫科（邮编300308）
2 天津市免疫系统疾病临床医学研究中心
3 天津医科大学公共卫生学院
4 天津医科大学总医院风湿免疫科

收稿日期:2025-04-10 修回日期:2025-09-29 出版日期:2026-01-15 发布日期:2026-01-19
通讯作者: ^△ E-mail：limbourg@163.com
作者简介:李荣琪（1998），女，医师，主要从事风湿免疫疾病方面研究。E-mail：lirongqi1202@163.com

Clinical significance of serum interferon regulatory factor 1 in rheumatoid arthritis

LI Rongqi¹^,²(), LI Yuxuan³, ZHANG Yan¹^,², LI Xin²^,⁴^,^△(), WEI Wei²^,⁴

1 Departments of Rheumatology and Immunology, Tianjin Medical University General Hospital Airport Hospital, Tianjin 300308, China
2 Tianjin Clinical Research Center for Rheumatic and Immune Diseases
3 Tianjin Medical University School of Public Health
4 Departments of Rheumatology and Immunology, Tianjin Medical University General Hospital

Received:2025-04-10 Revised:2025-09-29 Published:2026-01-15 Online:2026-01-19
Contact: ^△ E-mail：limbourg@163.com

李荣琪, 李宇轩, 张燕, 李昕, 魏蔚. 血清干扰素调节因子1在类风湿关节炎中的临床意义[J]. 天津医药, 2026, 54(1): 84-87.

LI Rongqi, LI Yuxuan, ZHANG Yan, LI Xin, WEI Wei. Clinical significance of serum interferon regulatory factor 1 in rheumatoid arthritis[J]. Tianjin Medical Journal, 2026, 54(1): 84-87.

摘要/Abstract

摘要：

目的探讨血清干扰素调节因子1（IRF1）在类风湿关节炎（RA）中的临床意义。方法纳入30例RA患者（RA组）和30例健康者（对照组）作为研究对象，采用酶联免疫吸附试验检测受试者血清IRF1、抗环瓜氨酸肽抗体（抗CCP抗体）水平，收集RA患者的临床资料及实验室指标，如健康评估问卷（HAQ）、白细胞介素-6（IL-6）、28个关节疾病活动指数（DAS28-ESR）评分等。RA患者以单药甲氨蝶呤起始治疗（10~20 mg/周）1~3个月，分别于第4和12周经DAS28-ESR评估疗效，必要时调整治疗方案；期间可短期联用小剂量激素或非甾体抗炎药以快速缓解症状。比较RA组和对照组以及RA组治疗前后的血清IRF1和抗CCP抗体水平；分析IRF1与RA患者临床和实验室指标之间的相关性；受试者工作特征（ROC）曲线评估IRF1对RA的诊断价值。结果与对照组相比，RA组血清IRF1、抗CCP抗体水平均升高。RA组血清IRF1浓度与抗CCP抗体、红细胞沉降率、C反应蛋白、DAS28-ESR评分、关节压痛计数、关节肿胀计数、疼痛视觉模拟评分、HAQ、IL-6、类风湿因子无相关性（P>0.05）。接受MTX治疗4周后RA患者血清IRF1水平较治疗前差异无统计学意义（P>0.05）；至第12周血清IRF1水平较治疗前和治疗后4周均降低（P<0.05）。血清IRF1与抗CCP抗体联合诊断RA的曲线下面积为0.968（95%CI：0.924~1.000），优于二者单独诊断（AUC分别为0.831、0.852）。结论 RA患者血清IRF1水平增高，对RA有一定的诊断价值，且与血清抗CCP抗体联合诊断效能更高。

关键词: 关节炎, 类风湿, 干扰素调节因子1, 自身抗体, 甲氨蝶呤, 抗CCP抗体

Abstract:

Objective To investigate the clinical significance of serum interferon regulatory factor 1 (IRF1) in rheumatoid arthritis (RA) patients. Methods Thirty patients with RA and 30 healthy individuals (control group) were included in this study. The serum levels of IRF1 and anti-cyclic citrullinated peptide (anti-CCP) antibody were detected by enzyme-linked immunosorbent assay. Assessment questionnaire (HAQ), interleukin-6 (IL-6) and disease activity score (DAS) 28-ESR were collected from the RA patients. Patients with RA received initial methotrexate (MTX) monotherapy (10-20 mg weekly) for 1-3 months. Disease activity was assessed using the DAS28-ESR at weeks 4 and 12, and the treatment regimen was adjusted if necessary. Short-term, low-dose corticosteroids or nonsteroidal anti-inflammatory drugs could be used concomitantly for rapid symptom relief. The serum levels of IRF1 and anti-CCP antibody were compared before and after treatment between the RA group and the control group. Spearman's correlation analysis was used to analyze the correlation between IRF1 and clinical and laboratory indicators of RA patients. The diagnostic value of IRF1 for RA was assessed by receiver operating characteristic (ROC) curve. Results Serum IRF1 and anti-CCP antibody levels were significantly higher in the RA group compared with those of the control group. No significant correlation was found between serum IRF1 concentration and anti-CCP antibodies, ESR, CRP, DAS28-ESR, TJC, SJC, VAS, HAQ, IL-6 and RF (P>0.05). After receiving methotrexate treatment for 4 weeks, the serum IRF1 level of RA patients showed no significant change compared to baseline (P>0.05). By the 12th week, the serum IRF1 level decreased significantly compared with that of treatment for 4 week and pre-treatment (P<0.05). The area under ROC curve (AUC) of IRF1 and anti-CCP antibody combined for RA diagnosis was 0.968 (95%CI:0.924-1.000), which was better than the single diagnosis of IRF1 or anti-CCP antibody (AUC was 0.831 and 0.852, respectively). Conclusion Serum IRF1 level is increased in RA patients. IRF1 has a certain diagnostic value in RA, and the combined diagnostic efficiency with anti-CCP antibody is higher.

Key words: arthritis, rheumatoid, interferon regulatory factor-1, autoantibodies, methotrexate, anti-CCP antibody

中图分类号:

R593.22

图/表 4

参考文献 15

[1]	薛乐乐, 鄂林宁. 类风湿关节炎相关间质性肺疾病的CT与MRI应用进展[J]. 国际医学放射学杂志, 2023, 46(5):556-561.
	XUE L L, E L N. Research progress of CT and MRI in rheumatoid arthritis-related interstitial lung disease[J]. Int J Med Radiol, 2023, 46(5):556-561. doi:10.19300/j.2023.Z20526.
[2]	FINCKH A, GILBERT B, HODKINSON B, et al. Global epidemiology of rheumatoid arthritis[J]. Nat Rev Rheumatol, 2022, 18(10):591-602. doi:10.1038/s41584-022-00827-y.
[3]	耿研, 谢希, 王昱, 等. 类风湿关节炎诊疗规范[J]. 中华内科杂志, 2022, 61(1):51-59.
	GENG Y, XIE X, WANG Y, et al. The standardized diagnosis and treatment of rheumatoid arthritis[J]. Chin J Intern Med, 2022, 61(1):51-59. doi:10.3760/cma.j.cn112138-20210616-00426.
[4]	海峡两岸医药卫生交流协会风湿免疫病学专业委员会慢病管理学组. 类风湿关节炎慢病管理专家指导建议[J]. 中华内科杂志, 2023, 62(11):1256-1265.
	Chronic Disease Management Group of the Rheumatology and Immunology Committee of the Cross-Strait Medical and Health Exchange Association. Expert recommendations for the chronic disease management of rheumatic arthritis[J]. Chin J Intern Med, 2023, 62(11):1256-1265. doi:10.3760/cma.j.cn112138-20221219-00940.
[5]	LIU J, BERTHIER C C, KAHLENBERG J M. Enhanced inflammasome activity in systemic lupus erythematosus is mediated via type i interferon-induced up-regulation of interferon regulatory factor 1[J]. Arthritis Rheumatol, 2017, 69(9):1840-1849. doi:10.1002/art.40166.
[6]	MAROTTE H, TSOU P S, RABQUER B J, et al. Blocking of interferon regulatory factor 1 reduces tumor necrosis factor α-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein a:role of the nuclear interferon regulatory factor 1-NF-κB-c-jun complex[J]. Arthritis Rheum, 2011, 63(11):3253-3262. doi:10.1002/art.30583.
[7]	ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis,2010, 69(9):1580-1588. doi:10.1136/ard.2010.138461.
[8]	KONDO N, KURODA T, KOBAYASHI D. Cytokine networks in the pathogenesis of rheumatoid arthritis[J]. Int J Mol Sci, 2021, 22(20):10922. doi:10.3390/ijms222010922.
[9]	许文静, 高冬梅, 李慧心, 等. 类风湿关节炎患者血清脂肪因子趋化素与疾病活动度和Th17/Treg的关系[J]. 天津医药, 2024, 52(2):193-196.
	XU W J, GAO D M, LI H X, et al. Correlation analysis of serum Chemerin with disease activity and Th17/Treg in patients with rheumatoid arthritis[J]. Tianjin Med J, 2024, 52(2):193-196. doi:10.11958/20230505.
[10]	FUJITA T, SAKAKIBARA J, SUDO Y, et al. Evidence for a nuclear factor(s),IRF-1,mediating induction and silencing properties to human IFN-beta gene regulatory elements[J]. EMBO J, 1988, 7(11):3397-3405. doi:10.1002/j.1460-2075.1988.tb03213.x.
[11]	TADA Y, HO A, MATSUYAMA T, et al. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1[J]. J Exp Med, 1997, 185(2):231-238. doi:10.1084/jem.185.2.231.
[12]	YOSHIDA S, ARAKAWA F, HIGUCHI F, et al. Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection:up-regulation of inflammation-associated STAT1,IRF1,CXCL9,CXCL10,and CCL5[J]. Scand J Rheumatol, 2012, 41(3):170-179. doi:10.3109/03009742.2011.623137.
[13]	BONELLI M, DALWIGK K, PLATZER A, et al. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes :JAKinibs suppress the interferon response in RA-FLSs[J]. Exp Mol Med, 2019, 51(7):1-11. doi:10.1038/s12276-019-0267-6.
[14]	郭书婷, 张瑞雪, 延峰. 血清阴性类风湿关节炎3例并文献复习[J]. 风湿病与关节炎, 2022, 11(2):29-32.
	GOU S T, ZHANG R X, YAN F. Three cases of serum negative rheumatoid arthritis and literature review[J]. Arthritis Rheum, 2022, 11(2):29-32. doi:10.3969/j.issn.2095-4174.2022.02.007.
[15]	SOUTO-CARNEIRO M, TÓTH L, BEHNISCH R, et al. Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis[J]. Ann Rheum Dis, 2020, 79(4):499-506. doi:10.1136/annrheumdis-2019-216374.

组别	n	IRF1/（μg/L）	抗CCP抗体/（U/mL）
对照组	30	4.145（3.591，4.641）	12.000（8.750，15.000）
RA组	30	6.087（4.844，6.450）	81.200（25.650，466.575）
Z		4.406^＊	4.691^＊

组别	n	IRF1/（μg/L）	抗CCP抗体/（U/mL）
对照组	30	4.145（3.591，4.641）	12.000（8.750，15.000）
RA组	30	6.087（4.844，6.450）	81.200（25.650，466.575）
Z		4.406^＊	4.691^＊

各项指标	参数	r_s	P
ESR/（mm/1 h）	41.433±2.818	-0.060	0.752
CRP/（mg/L）	14.10（7.15，24.70）	-0.124	0.514
DAS28-ESR/分	5.443±0.201	-0.154	0.417
TJC/个	9.870±1.069	0.003	0.987
SJC/个	2.500（2.000，4.250）	-0.074	0.698
疼痛VAS评分/分	5.530±0.358	-0.178	0.347
HAQ/分	9.000（3.750，18.000）	-0.046	0.809
IL-6/（μg/L）	44.495（28.090，59.542）	-0.334	0.071
RF/（IU/mL）	146.500（26.075，408.500）	0.063	0.740

各项指标	参数	r_s	P
ESR/（mm/1 h）	41.433±2.818	-0.060	0.752
CRP/（mg/L）	14.10（7.15，24.70）	-0.124	0.514
DAS28-ESR/分	5.443±0.201	-0.154	0.417
TJC/个	9.870±1.069	0.003	0.987
SJC/个	2.500（2.000，4.250）	-0.074	0.698
疼痛VAS评分/分	5.530±0.358	-0.178	0.347
HAQ/分	9.000（3.750，18.000）	-0.046	0.809
IL-6/（μg/L）	44.495（28.090，59.542）	-0.334	0.071
RF/（IU/mL）	146.500（26.075，408.500）	0.063	0.740

指标	AUC（95%CI）	截断值	敏感度/ %	特异度/ %	约登指数
IRF1	0.831（0.718~0.944）	4.774 μg/L	83.3	80.0	0.633
抗CCP抗体	0.852（0.736~0.969）	21 U/mL	100.0	80.0	0.800
IRF1+抗 CCP抗体	0.968（0.924~1.000）		96.7	96.3	0.900

血清干扰素调节因子1在类风湿关节炎中的临床意义

Clinical significance of serum interferon regulatory factor 1 in rheumatoid arthritis

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 4

参考文献 15

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王婷, 王丹, 李瑛. 血清自身抗体变化对不明原因复发性流产患者妊娠结局的影响及预测模型构建[J]. 天津医药, 2025, 53(8): 831-835.
[2]	何仁豪, 张聘, 尹识渊, 张杰. 关节镜探查联合单髁置换术对膝关节骨性关节炎患者膝关节功能的影响[J]. 天津医药, 2025, 53(7): 725-729.
[3]	钟玉梅, 何流, 张敏, 周海燕. 艾灸调控巨噬细胞不同表型极化治疗RA滑膜炎症的疗效[J]. 天津医药, 2025, 53(3): 236-241.
[4]	崔琳, 李海晴, 陈雨彤, 朱佳璇, 王璐怡. 经皮神经电刺激联合动态关节松动术对膝骨关节炎疗效观察[J]. 天津医药, 2025, 53(12): 1285-1289.
[5]	吕婧, 朱方颖, 朱凯, 李云, 杨娜, 温淑云, 仲米倩. 类风湿关节炎患者动脉粥样硬化风险预测模型的构建与验证[J]. 天津医药, 2025, 53(10): 1043-1047.
[6]	吴斌, 刘兆祥, 张月红, 王昌耀. 过度机械应力调控Piezo1介导成软骨细胞铁死亡的机制探讨[J]. 天津医药, 2025, 53(1): 14-18.
[7]	钟玉梅, 周海燕, 张敏. ASIC1a介导类风湿关节炎软骨细胞损伤机制的研究进展[J]. 天津医药, 2024, 52(9): 1004-1008.
[8]	尹韦玉, 廖红丽, 刘媛. SS相关抗体在特发性炎症性肌病及其相关间质性肺炎中的临床意义[J]. 天津医药, 2024, 52(7): 695-700.
[9]	罗宴冉, 史晓飞, 韩磊, 张贝, 文路遥. 皮肌炎自身抗体在间质性肺病中的研究进展[J]. 天津医药, 2024, 52(7): 704-708.
[10]	袁满, 冯子瀚, 谢敏, 王柏军. 大黄素对骨关节炎模型小鼠痛觉行为的调节机制[J]. 天津医药, 2024, 52(6): 572-577.
[11]	罗锟, 王智, 王柯. 山姜素调节VEGF/SphK1/S1P信号通路对膝骨关节炎大鼠血管生成的影响[J]. 天津医药, 2024, 52(5): 480-485.
[12]	初吉燕, 田竞, 付笛语, 郭琳, 孙蕊, 李萍. AIM2炎症小体在急性痛风性关节炎中的表达及意义[J]. 天津医药, 2024, 52(5): 518-522.
[13]	王柯, 叶寒露. 隐丹参酮调节HIF-1α/BNIP3信号通路对兔膝骨关节炎模型软骨细胞自噬和凋亡的影响[J]. 天津医药, 2024, 52(4): 372-378.
[14]	乔坤艳, 刘韦娜, 郑晓雅, 苏瑞, 杨悦杰. 布鲁氏菌病患者外周血白细胞及血小板参数的变化及临床意义[J]. 天津医药, 2024, 52(4): 391-396.
[15]	许文静, 高冬梅, 李慧心, 王莉, 佟胜全. 类风湿关节炎患者血清脂肪因子趋化素与疾病活动度和Th17/Treg的关系[J]. 天津医药, 2024, 52(2): 193-196.